A comparative study of atorvastatin and rosuvastatin in dyslipidemia

Rudip Thapa¹*, Prakash Rai¹, Laxmi Mahara², Sudarsana Chetty³

¹Department of Clinical Pharmacology, Nepal Medical College, Atterkhel, Kathmandu, Nepal
²International Friendship Children’s Hospital, Maharajgunj, Kathmandu, Nepal
³Department of Pharmacology, College of Medical Science, Bharatpur, Nepal

Received: 05 September 2017
Accepted: 03 October 2017

*Correspondence to:
Rudip Thapa,
Email: thaparudip88@gmail.com

ABSTRACT

Background: To compare the drugs: Atorvastatin (10mg) and Rosuvastatin (5mg) in patients with Dyslipidemia.

Methods: This open-label, randomized, parallel group, comparative, prospective study of six months duration included 100 patients. The age group of patients varied from 30 to 69 years with dyslipidemia. Patients were divided in to 2 groups. 50 patients in group-1 received Atorvastatin 10mg once daily and 50 patients in group-2 received Rosuvastatin 5 mg once daily. The level of TC, TG, LDL, VLDL and HDL were assessed at baseline and at the end of 3 months and 6 months.

Results: At 3 months, LDL was reduced significantly more with 5mg Rosuvastatin than with Atorvastatin 10 mg [43.68% vs. 40.74% (P 0.0049)]. At 6 months, Rosuvastatin 5mg reduced LDL significantly more than Atorvastatin 10 mg [48.69% vs. 43.85% (P 0.00)]. TC, HDL, TG and VLDL were more favourably modified by Rosuvastatin at 6 months (P <0.005). Reduction of total cholesterol levels in Rosuvastatin group was not statistically significant when compared with Atorvastatin group (P 0.103).

Conclusions: Rosuvastatin 5mg was more efficacious than Atorvastatin 10mg for the improvement of lipid profile during the period of 6 months follow-up drug therapy in patients with dyslipidemia.

Keywords: Atorvastatin, Dyslipidemia, Rosuvastatin

INTRODUCTION

Worldwide, hypercholesterolemia cause about 56% of ischemic heart disease and 18% of strokes, resulting to 4.4 million deaths annually. Hyperlipidemia and the rates of hypercholesterolemia (total cholesterol ≥201.1mg/dl) increased from 18% to 31% in adults aged 35-59. Studies have shown that the risk of ischemic heart disease in individuals with hypercholesterolemia is about thrice as great as in those with normal plasma cholesterol level indicating that reduction in plasma cholesterol does reduce the risk of myocardial infraction. There is increasing evidence that Hyperlipidemia is a major cause of atherosclerosis and atherosclerosis-associated conditions, such as coronary heart disease (CHD), ischemic cerebrovascular disease and peripheral vascular disease and reduction of TC and LDL-C below 442.86mg/dl and 116mg/dl, respectively, lowers the incidence of CHD. The lifetime risk of developing CHD after 40 years of age is 49% in men and 32% in women. Even at 70 years of age, the risk is 35% for men and 24% for women. The lifetime risk of developing CVD at 50 years of age is estimated to be 1 in 2 for men and 2 in 5 for women in USA only. Numerous epidemiologic investigations have suggested that age, sex, elevated LDL-
C level, low HDL-C level, DM, alcoholism and smoking are key risk factors for CHD. There is growing evidence that Statins, beyond their LDL cholesterol-lowering effects, possess so-called pleiotropic effects that could be have beneficial effects for patients with cardiovascular disease. Several observational studies suggest a large reduction in mortality in patients with ACS who were treated with Statins that were started prior to hospital discharge. In contrast, a recent meta-analysis concluded that initiation of Statin therapy within 14 days following onset of ACS does not reduce death, MI, or stroke as evaluated at 4-month follow-up. Additional studies evaluated the efficacy of an intensive Statin therapy in ACS patients. The PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) trial enrolled 4162 patients with a recent diagnosis of ACS (STEMI in one-third of the total) and demonstrated that an intensive (Atorvastatin 80mg daily, target LDL-C <70mg/dl) versus a moderate (Pravastatin 40mg daily, target LDL-C <100mg/dl) lipid-lowering strategy is more effective in reducing the incidence of death or major cardiovascular events.

Plasma lipids consist of cholesterol (14%), triacylglycerols (16%), phospholipids (30%), and cholesteryl esters (36%) and a much smaller fraction of unesterified long-chain fatty acids (free fatty acids) (4%). The free fatty acids (FFA), is metabolically the most active of the plasma lipids.

Study on hypolipidemic drugs on lipid profile has been carried out many times in India, China, Japan, and UK, USA and other countries, which shows the relationship between hypolipidemic drugs in maintaining lipid profile. In Nepal this may be the very first study of its kind which will help to provide related data about the effect of Statins on lipid profile in Nepalese population. Due to more sedentary lifestyle at old age and use of alcohol and smoking, Nepalese population are being more prone to cardiovascular diseases like Hypertension, CAD etc. Mainly low level of HDL-C and elevated TG and LDL-C are clearly associated with excess risk of CVD and this association holds across racial and ethnic divisions.

METHODS

It is a hospital based open label comparative study of 100 patients above 15 years of age with case of Dyslipidemia. The study was conducted in out patient and admitted patient after obtaining written consent in CMSTH (College of Medical Sciences- Teaching Hospital), Bharatpur, Chitwan, Nepal during December 2010 to June 2011 with an aim to find out the effect of two Statins i.e. Atorvastatin and Rosuvastatin on lipid profile. Randomly selected 100 cases of dyslipidemia meeting the inclusion criteria (Modified NCEP ATP III criteria, Table 1) in to 2 groups. Each group contains 50 patients and given Atorvastatin 10mg and Rosuvastatin 5mg. Each case was followed up after 3 months and 6 months. After taking history and clinical examination, Fasting Serum TC, TG, HDL, LDL and VLDL level were measured. Patients were excluded if they were pregnant or had malignancy, having active arterial disease such as unstable angina, myocardial infarction, cerebrovascular accident, coronary artery bypass surgery, or angioplasty within 2 months prior to study. Liver disease, Malnutrition, Hyperthyroidism, Infection with hepatitis C virus (HCV), and Patients taking oral contraceptives are also excluded.

| Table 1: The ATP III guideline recommends total cholesterol level. |
|-----------------|-----------------|
| Unit mg/dl     |                |
| <200mg/dl      | Desirable       |
| 200-239mg/dl   | Borderline high |
| ≥240mg/dl      | High            |

Data was recorded on predesigned proforma. Results were expressed as mean, standard deviation and LSM % change. Different statistical test of significance (student’s ‘t’ test and chi square test) were applied to find the p value. P value less than 0.05 was considered statistically significant.

RESULTS

Total of 100 patients were involved in the study, mean age was 49±8.83 years out of which 54 were female and 46 males. Among 50 patients receiving Atorvastatin, 30 were male and 20 were female and the mean age was 47.64±10.39 years. The mean age of group receiving Rosuvastatin was 50±8.26 years of which 24 were male and 26 were female. According to ethnicity 30% were Brahmins, 27% were Chhetry and Thakuri, 21% Mongols like Gurungs, Rai, Tamang, Pun, Lama, Rana and 22% were other which include Chaudhary, Maheto, Yadav, Pariyar. The demography shows that 89% of the patients were involved in either smoking or in consumption of alcohols or having past history of either of them. The age of the patients in study group ranged from 30 years to 70 years with a mean age of 49.12 years.

| Table 2: Patient demographics and baseline characteristics (randomized population). |
|-----------------|-----------------|-----------------|-----------------|
| Lipid profile   | Atorvastatin 10mg Mean±SD | Rosuvastatin 5mg Mean±SD |
| TC              | 265.39±15.57    | 272.03±17.39    |
| TG              | 220.51±40.77    | 227.13±38.49    |
| HDL             | 38.14±7.43      | 40.15±6.18      |
| LDL             | 183.12±13.72    | 186.54±13.39    |
| VLDL            | 44.1±8.20       | 45.45±7.7       |

Number of male and female patients was 54 and 46 respectively. This indicated higher incidence of dyslipidemia in male patients. The maximum number of dyslipidemia patients was found in age group between 41-60 (41%) of which 33 were male and 40 were female. Brahmins ethnicity patients had higher percentage (30%).
of dyslipidemia followed by Chhetry and Thakuri (27%), Mongols (21%) and others 22% including Chaudhary, Maheto, Yadav, Pariyar. Total of 89% of subject intention to treat had past history of either alcohol or smoking or both.

The two groups were well matched at baseline and demographic details were obtained which is shown in tables below. Patient demographics and the mean baseline at initial stage of study (Table 2), at three months (Table 3) and six months (Table 4) were obtained with LSM change in percentage in lipid parameters.

Rosuvastatin 5mg increased HDL-C levels to a significantly greater extent than atorvastatin 10mg (mean change 6.4% and 3.1%, p <0.001), while similar reductions in TC, TG, and non HDL-C levels were observed with both treatments.

**Table 3: Change from baseline in lipoprotein and lipid levels after 3 months of treatment.**

<table>
<thead>
<tr>
<th>Lipid profile</th>
<th>Atorvastatin 10mg</th>
<th>Rosuvastatin 5mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean baseline level, mg/dL±SD</td>
<td>LSM percentage change</td>
</tr>
<tr>
<td>TC</td>
<td>177.87±11.35</td>
<td>32.9</td>
</tr>
<tr>
<td>TG</td>
<td>149.81±20.66</td>
<td>31.12</td>
</tr>
<tr>
<td>HDL</td>
<td>39.75±7.41</td>
<td>4.12</td>
</tr>
<tr>
<td>LDL</td>
<td>108.39±8.52</td>
<td>40.74</td>
</tr>
<tr>
<td>VLDL</td>
<td>29.94±4.12</td>
<td>31.16</td>
</tr>
</tbody>
</table>

**Table 4: Change from baseline in lipoprotein and lipid levels after 6 months of treatment.**

<table>
<thead>
<tr>
<th>Lipid profile</th>
<th>Atorvastatin 10mg</th>
<th>Rosuvastatin 5mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean baseline level, mg/dL±SD</td>
<td>LSM percentage change</td>
</tr>
<tr>
<td>TC</td>
<td>172.5±11.21</td>
<td>34.94</td>
</tr>
<tr>
<td>TG</td>
<td>140.6±19.48</td>
<td>35.42</td>
</tr>
<tr>
<td>HDL</td>
<td>41.72±7.58</td>
<td>8.71</td>
</tr>
<tr>
<td>LDL</td>
<td>102.69±8.2</td>
<td>43.85</td>
</tr>
<tr>
<td>VLDL</td>
<td>28.12±3.89</td>
<td>35.42</td>
</tr>
</tbody>
</table>

**DISCUSSION**

Data from two groups were analyzed for an efficacy comparison in the intention-to-treat population. Baseline values of all parameters were similar between the two groups. The mean Serum TC, TG, LDL-C and VLDL-C levels were significantly reduced on therapy. Simultaneously, the mean level of HDL-C was highly significantly increased after therapy with both Atorvastatin and Rosuvastatin. At 3 months duration of drug treatment, Atorvastatin 10mg reduced the level of TC by 32.9% which is similar with the findings of Kuryata et al, TG by 31.12%, LDL-C 40.74% as reported by Zhonghu et al, and VLDL-C 31.16% respectively. The level of HDL-C was increased by 4.12% which is similar as reported by Zhonghu et al, and at 6 months duration Atorvastatin 10mg reduced the level of TC by 34.94%, TG by 35.42%, LDL-C 43.85 % and VLDL-C 35.42% respectively. The level of HDL-C was increased by 8.71% as reported by Save et al.

At 3 months duration of drug treatment, Rosuvastatin 5mg reduced the level of TC by 31.67% and LDL-C 43.68% which is similar with the findings of Teramoto et al, and VLDL-C 31.16%. The level of HDL-C was increased by 10.19% which is similar as reported by Teramoto et al, and at 6 months of duration Rosuvastatin 5mg reduced the level of TC by 35.01%, TG by 25.56%, LDL-C 48.69% and VLDL-C 25.6% respectively. The level of HDL-C was increased by 15.5%.

This study showed that Rosuvastatin 5mg has better efficacy in comparison to Atorvastatin 10mg for the treatment of Dyslipidemia. While comparing mean % reduction, both groups of patients had significant reduction in lipids and lipoprotein levels during 6 months of drug treatment. Rosuvastatin enabled significantly more patients to achieve the National Cholesterol Education Program (NCEP) goals compared to Atorvastatin with LDL-C (74% vs 48%), TC (100% vs 98%), HDL (male 52.94% vs 48%, female 50% vs 26%). Number of patients to achieve the National Cholesterol Education Program (NCEP) goals for TG were found more in Atorvastatin group compared to Rosuvastatin (66% vs 30%). As many clinical trail observations have demonstrated the superiority of Rosuvastatin over Atorvastatin in lowering
level of LDL-C, TG, TC, VLDL-C and raising level of HDL-C, my study also has similar pattern of findings. At 6 months of drug treatment, Rosuvastatin 5mg produced a significantly greater reduction in TC, LDL-C, TG and VLDL-C in compared to Atorvastatin 10mg. Rosuvastatin 5mg also significantly raised HDL-C level than Atorvastatin 10mg in this study.

Schwartz et al, in the study of 383 cases of hypercholesterolemia and high risk of CHD patients at 3 months of drug treatment with Rosuvastatin 5mg/day and Atorvastatin 10mg/day found to decrease LDL-C by 40% and 35% respectively. TC, HDL-C, and VLDL-C were more favourably modified by Rosuvastatin at 6 months of drug treatment which is similar to the result with my study. Effects of the both agents on TG were similar as reported by my study.

Blasetto et al, report significant improvement in lipids and lipoprotein levels with the treatment of Rosuvastatin 5mg compared to that with Atorvastatin 10mg which is very similar to the result in my study. A similar comparative study done by Schneck et al, on 374 hypercholesterolemia patients without active arterial disease showed that Rosuvastatin was significantly effective in compared to Atorvastatin in maintaining lipid profile which is similar with the result of my study.

Davidson et al, in the study of 516 North American population found that Rosuvastatin 5mg/day in compared to Atorvastatin 10mg/day were associated with greater in LDL-C, reduction and HDL-C increase which is similar with the result of my study. Reduction in the TC and TG did not match with result of my study of 3 months periods. The possible explanation for this conflicting result may be that, patients in my study did not have any dietary run-in before the drug therapy. The sample size also being small in my study may be the cause.

Kurabayashi et al, in the study with Japanese patients found that Rosuvastatin 5mg/day is a useful treatment option than Atorvastatin 10mg/day for high risk patients with hypercholesterolemia which is similar with the result of my study.

Park et al, in the study with 351 Korean patients with metabolic syndrome and hypercholesterolemia found greater reduction in TC and LDL-C level by Rosuvastatin treatment as compared to Atorvastatin treatment which is similar with the result of my study.

A 48 week randomized, parallel group, open label study done in 106 patients with primary hypercholesterolemia by Mazza et al, showed that Rosuvastatin was associated with significantly greater reduction in LDL-C, TC, and TG compared to Atorvastatin which resembles with the result of my study.

A comparative study done by Otokozawa et al, also showed that maximum dose Rosuvastatin 40mg/day was significantly more effective than Atorvastatin 80mg/day in reducing LDL-C, TG and TC which supports the result of my study. Similar study done by Lloret et al, also showed that Rosuvastatin significantly decreases lipid and lipoproteins level compared with Atorvastatin is also supportive to the result of my study.

Olsson et al, report Rosuvastatin 5mg/day was associated with significantly greater LDL reduction than Atorvastatin 10mg/day which is similar with the result of my study.

CONCLUSION

The result of this study shows that at recommended dose, Rosuvastatin (5mg/day) was more efficacious than Atorvastatin (10mg/day), in terms of improving lipid profile in the period of 6-month follow-up. The greater efficacy of Rosuvastatin at recommended dose should help to enable more patients to achieve recommended treatment goals in clinical practice. In addition, improvements across the whole lipid profile may provide further reductions in the risk of CVD. With the goal of more improvements in lipid profile, further study will be needed to determine whether more stringent statin monotherapy or combination treatment is needed for better outcomes in patients with the Dyslipidemia.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES


